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Abstract 
 
Background: Phase 3 trials of the efficacy and safety of the candidate malaria vaccine 
RTS,S/AS01 are complete, but site-specific data are limited. This study assesses the interaction 
of precipitation and vaccine efficacy and corresponding estimates of clinical malaria episodes 
averted in a seasonal-transmission region of sub-Saharan Africa. 
 
Methods: We followed children (5-17 months of age) and infants (6-12 weeks of age) who had 
been randomly assigned to one of three groups: 1) a group that received 3 doses of RTS,S and a 
booster dose 18 months after the third dose (R3R group); 2) a group that received the same 
schedule without the booster (R3C group); 3) a control group –the rabies vaccine (VeroRab, 
Sanofi-Pasteur) was administered to children 5-17 months of age and the meningococcal 
serogroup C conjugate vaccine (Menjugate, Novartis) was administered to infants 6-12 weeks of 
age (C3C group). Primary efficacy was defined as development of clinical malaria (fever 
≥37.5°C and Plasmodium falciparum parasitemia density >5,000 parasites per microliter) for 
both age groups. Patients were followed passively but were told to seek medical care at a 
designated Health Center for any illness. Precipitation data were obtained from the Chitedze 
Agricultural Center in Lilongwe, Malawi (-13.97S, 33.63E, 3770 ft). 
 
Findings: Over the duration of follow-up, 744 of 1513 (49.1%) children and infants had at least 
1 episode of clinical malaria. Among children, vaccine efficacies were 42.7% (95% CI 25.7%, 
55.8%, P<0.0001) for the R3R group and 33.1% (95% CI 14.5%, 47.7%, P=0.001) for the R3C 
group for first malaria case. Among infants, vaccine efficacies were 41.8% (95% CI 24.4%, 
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53.7%, P<0.0001) for the R3R group and 29.9% (95% CI 11.3%, 44.6%, P=0.003) for the R3C 
group. Precipitation was significantly associated with increased malaria incidence, with each 1-
inch increase in rainfall per month elevating the hazard of malaria by 12.6% (95% CI 9.6%, 
15.6%) among children and by 15.9% (95% CI 12.8%, 18.9%) among infants. Vaccine efficacy 
was not affected by seasonal variations in precipitation. 
 
Interpretations: Policy discussions for the expanded use of RTS,S/AS01 are underway. It will 
be critical to determine the performance of the vaccine according to the seasonal pattern of 
malaria transmission. We show that vaccine efficacy does not change during the rainy or dry 
season in Lilongwe, Malawi, an area of mesoendemic, seasonal transmission. 
 
Keywords: RTS,S/AS01, malaria vaccine efficacy, seasonal transmission, precipitation, Malawi 
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Introduction 
 
Globally, malaria incidence among populations at-risk fell by 37% between 2000 and 2015, with 
malaria death rates among children under 5 years of age reduced by 65%.1 Despite substantial 
financial and developmental resources directed toward reducing malaria incidence in sub-
Saharan Africa, Malawi has not seen a significant decrease in malaria transmission. The 
population of Malawi is under a mesoendemic transmission risk for malaria2, but it was found to 
be one of only two (out of 44) malaria-endemic countries that saw an increase in a population-
adjusted Plasmodium falciparum parasite rate among children aged 2-10 years.3  
 
The multi-site, Phase 3 trial of RTS,S/AS01, the most advanced candidate malaria vaccine, is 
complete. Across 11 study sites in seven countries in sub-Saharan Africa, administration of the 
vaccine in four doses was shown to reduce clinical malaria by 36.3% (95% confidence interval 
[CI] 31.8%, 40.5%) in children 5-17 months of age and by 25.9% (95% CI, 19.9%, 31.5%) in 
infants 6-12 weeks old.4  The European Medicines Agency has adopted a positive scientific 
opinion of the vaccine, leading to a recommendation by WHO’s Strategic Advisory Group of 
Experts on Immunization (SAGE) and the Malaria Policy Advisory Committee (MPAC) to 
implement large-scale pilot projects.1  
 
Policy discussions for the expanded use of RTS,S/AS01 are thus underway. To inform these 
policy discussions it will be critical to understand the variation in vaccine efficacy over space 
and time. It is widely understood that RTS,S/AS01 will not serve as a panacea, and that the 
vaccine must be used in conjunction with other control measures such as the use of insecticide-
treated nets and prompt and appropriate artemisinin combination therapies. However, 
implementation of the vaccine may be particularly effective in certain environments, such as in 
areas where malaria transmission is high, seasonal or in elimination programs.5  
 
Site-specific data which considers the seasonality of vaccine efficacy have been limited. An 
understanding of the seasonality of transmission and temporal variations in each location are 
critical in deploying effective pilot interventions. For example, seasonal malaria 
chemoprevention is optimally targeted at regions with shorter, more intense malaria transmission 
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seasons, and requires accurate timing within that season.6 Mathematical models have also shown 
that a higher proportion of cases averted and high cost-effectiveness may be possible in lower 
transmission regions compared to higher transmission regions.7 We undertook an analysis of the  
phase 3 trial of RTS,S/AS01 in Lilongwe, Malawi, to evaluate its efficacy against episodes of 
clinical Plasmodium falciparum malaria across seasonal variations in precipitation. 
 
 
Methods 
 
Study Design and Participants 
 
The details of the study design have been described previously.8-10 Primary efficacy was defined 
as development of clinical malaria (fever ≥37.5°C and Plasmodium falciparum parasitemia 
density >5,000 parasites per microliter) for both age groups.8-10 Patients were followed passively 
but were told to seek medical care at specified health settings for any illness. Precipitation data 
were obtained from the Chitedze Agricultural Center in Lilongwe, Malawi (-13.97S, 33.63E, 
3770 ft). The trial protocol was approved by both the institutional review board (IRB) at UNC 
Chapel Hill and by the Malawi National Health Sciences Research Committee. Parents or legal 
representatives of all participants witnessed and provided informed consent at enrollment to the 
study. Non-literate parents indicated consent by giving a thumbprint in place of a signature. 
 
Randomization and Masking 
 
From June 2009 until January 2011, children aged 5-17 months and infants aged 6-12 weeks 
were recruited in Lilongwe and randomly assigned (1:1:1) by block randomization to one of 
three groups: 1) a group that received 3 doses of RTS,S and a booster dose 18 months after the 
third dose (R3R group); 2) a group that received the same schedule without the booster (R3C 
group); 3) a control group –the rabies vaccine (VeroRab, Sanofi-Pasteur) was administered to 
children 5-17 months of age and the meningococcal serogroup C conjugate vaccine (Menjugate, 
Novartis) was administered to infants 6-12 weeks of age (C3C group). 
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Procedures 
 
The treatment of malaria during the study was done in accordance with Malawi national 
guidelines and detected by passive surveillance. The Lilongwe vaccine trial catchment area was 
identified using neighborhood location information from patients who came to the Area 18 
Health Center in the previous year. We examined three different geographic data sources to 
identify the catchment area. To recruit participants, we conducted community-based information 
sessions for families with infants and children who met the enrollment age criteria. Flyers were 
also distributed in the identified communities.   
 
 
Statistical Analysis 
 
Our cohort included all children and infants who had received three doses of vaccine according 
to study protocol and for whom efficacy surveillance data were available 14 days after the third 
dose. 
 
Cox proportional-hazard models were used to assess first or only malarial episodes. Vaccine 
efficacy against multiple malarial episodes were calculated using negative binomial regression, 
the Andersen-Gill model, and the Prentice-Williams-Peterson (PWP) extension of the Cox 
regression. In the negative binomial regression, the logarithm of follow-up time was used as 
offset. Events occurring within 14 days following a malaria episode meeting the primary case 
definition were excluded to minimize counting treatment failures as an episode resulting from a 
new infection.11 The 95% confidence intervals and p-values on vaccine efficacy estimates, 
defined as 1 minus the incidence-rate ratio or hazard ratio, were calculated. 
 
The reduction in incidence of malaria attributable to the vaccine was calculated as the difference 
between malaria incidence in the C3C group and the incidence in the vaccine groups (R3R or 
R3C), respectively. The result was expressed as the number of cases averted per 100 person-
years of follow-up.  
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Data were censored at the end of the follow-up period for each participant or at the date of 
emigration, withdrawal of consent, or death. Data were analyzed using SAS software, version 
9.4. 
 
 
Results 
 
Study Participants 
 
A total of 1626 participants in Lilongwe were randomly assigned to a treatment group. Among 
the 800 children, 261 were randomly assigned to receive C3C, 270 to R3C, and 269 to R3R. 
Among the 826 infants, 279 were randomly assigned to receive C3C, 275 to R3C, and 272 to 
R3R. A total of 1513 (93.1%) children and infants received the booster dose. Baseline 
characteristics were similar between the treatment groups within each age group, although 
children were followed-up for a longer period of time than infants (Table 1). 
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Table 1. Demographic characteristics at baseline and follow-up in our cohort 
 Children 
 
Infants  
Characteristic R3R 
(n=236) 
R3C 
(n=260) 
C3C 
(n=244) 
Total 
(n=740) 
R3R 
(n=253) 
R3C 
(n=252) 
C3C 
(n=265) 
Total 
(n=770) 
Follow-up 
time – mo  
    
     Median 45.4 45.1 45.5 45.3  33.8 33.9 34.4 34.1 
     10th-90th 
percentile 
20.9-
49.6 
19.3-
49.3 
21.4-
49.0 
19.9-
49.2 
20.8-
40.3 
20.5-
40.1 
25.2-
40.5 
21.8-
40.4 
Age at 
vaccination* 
        
     Median 12.1 11.6 11.2 11.7 7.8 7.9 8.1 7.9 
     Range 5.0-
17.0 
5.0-
17.0 
5.0-
17.0 
5.0-
17.0 
6.0-
12.0 
6.0-
12.0 
6.0-
12.0 
6.0-
12.0 
Sex – no. (%)     
     Female 116 
(49.2) 
134 
(51.5) 
116 
(47.5) 
366 
(49.5) 
115 
(45.5) 
122 
(48.4) 
133 
(50.2) 
370 
(48.1) 
     Male 120 
(50.8) 
126 
(48.5) 
128 
(52.5) 
374 
(50.5) 
138 
(54.5) 
130 
(51.6) 
132 
(49.8) 
400 
(51.9) 
*Ages given in months for children and in weeks for infants. 
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Efficacy against the first or only malaria episode 
 
In our cohort, 744 of 1513 (49.1%) children and infants had at least 1 episode of clinical malaria. 
Among children, 353 of 742 (47.5%) developed malaria – 96 of 237 (40.5%) in R3R group, 115 
of 260 (44.2%) in R3C group, 142 of 245 (57.8%) in the C3C group. Among infants, 391 of 771 
(50.7%) developed malaria – 107 of 253 (42.3%) in the R3R group, 123 of 252 (48.8%) in the 
R3C group, 161 of 266 (60.5%) in the C3C group (Table 2). 
 
Among children, vaccine efficacies were 42.7% (95% CI 25.7%, 55.8%, P<0.0001) for the R3R 
group and 33.1% (95% CI 14.5%, 47.7%, P=0.001) for the R3C group. Among infants, vaccine 
efficacies were 41.8% (95% CI 24.4%, 53.7%, P<0.0001) for the R3R group and 29.9% (95% CI 
11.3%, 44.6%, P=0.003) for the R3C group. Precipitation was significantly associated with 
increased malaria incidence, with each 1-inch increase in rainfall per month elevating the hazard 
of malaria by 12.6% (95% CI 9.6%, 15.6%) among children and by 15.9% (95% CI 12.8%, 
18.9%) among infants. Interaction terms between vaccine groups and precipitation were non-
significant. The interaction of R3R and precipitation gave a hazard ratio of 1.01 (95% CI 0.96, 
1.05) and the interaction of R3C and precipitation gave a hazard ratio of 1.00 (95% CI 0.96, 
1.04).  Kaplan-Meier failure curves of time until first or only malaria episode are shown for each 
age group (Fig. 1a, 1b).  
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Figure 1a. Kaplain-Meier failure curve of time-to-first-incidence of malaria among 
children 5-17 months of age, n=742 
 
 
Figure 1b. Kaplan-Meier failure curve of time-to-first-incidence of malaria among infants 
6-12 weeks of age, n=771 
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Efficacy against all episodes 
 
Four separate analyses were conducted to determine vaccine efficacy against all malaria 
episodes. The four models were a negative binomial regression model, which fitted the observed 
data better than the Poisson model (-2Loglikelihood=1379.17 with 1 df by the likelihood ratio 
test of overdispersion, P<0.0001) (Fig. 2) and three extensions of the Cox regression model for 
recurrent events – the Andersen-Gill (AG), the Prentice Williams Peterson total time (PWP-TT), 
and the Prentice Williams Peterson gap time (PWP-GT) models. The AG model is a counting 
process model that assumes time increments between malaria episodes are conditionally 
uncorrelated and that dependence between subsequent episodes is mediated through time-varying 
covariates.12 The PWP models order multiple episodes by stratification, i.e. all participants are 
considered at-risk for the first stratum but only those participants with an episode in the kth 
stratum are considered at risk for the (k+1)th stratum.  
 
Figure 2. Comparison of Poisson and Negative binomial distribution fits for observed 
clinical malaria cases 
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Multiple malarial episodes were common. From study initiation until study end, compared with 
391 episodes of clinical malaria that met the primary case definition in children in the C3C 
group, 193 episodes occurred in the R3R group and 288 occurred in the R3C group. In the infant 
group, compared with 545 episodes in the C3C group, 352 episodes occurred in the R3R group 
and 415 episodes occurred in the R3C group (Table 2).  
 
12 
 
Table 2. Event rates and efficacy of RTS,S/AS01 vaccine against episodes of Plasmodium falciparum clinical malaria 
 C3C R3C R3R 
 No. of 
individuals 
No. of 
events 
PYAR* Event 
rate 
No. of 
individuals 
No. of 
events 
PYAR* Event 
rate 
VE (95% 
CI) 
No. of 
individuals 
No. of 
events 
PYAR* Event 
rate 
VE (95% 
CI) 
Children 
First 
episode 
245 142 489.0 0.29 260 115 596.4 0.19 33.1 (14.5, 
47.7) 
237 96 580.7 0.17 42.7 (25.7, 
55.8) 
All 
episodes, 
negative 
binomial 
245 391 829.1 0.47 260 288 845.8 0.34 27.3 (5.0, 
44.4) 
237 193 787.3 0.25 48.8 (31.9, 
61.5) 
Infants 
First 
episode 
266 161 422.9 0.38 252 123 464.2 0.26 29.9 (11.3, 
44.6) 
253 107 482.1 0.22 41.8 (24.4, 
53.7) 
All 
episodes, 
negative 
binomial 
266 545 735.8 0.74 252 415 675.4 0.61 14.8 (-12.2, 
35.3) 
253 352 679.2 0.52 30.8 (8.6, 
47.7) 
*PYAR: person-years at risk
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Figure 3. Mean number of clinical malaria cases among treatment and age groups 
 
 
Compared to the C3C group, unadjusted efficacy against multiple episodes was 39.5% (95% CI 
26.1%, 50.5%; P<0.0001) in the R3R group and 20.9% (95% CI 4.0%, 34.9%; P=0.017) in the 
R3C group by the negative binomial regression. Adjusting for precipitation, efficacy against 
multiple episodes was 39.2% (95% CI 22.7%, 52.3%; P<0.0001) in the R3R group and 32.0% 
(95% CI 13.7%, 46.4%; P=0.001) in the R3C group, by the Andersen-Gill model. By the PWP 
total time model, efficacy against multiple episodes was 19.9% (95% CI 8.3%, 30.0%; P=0.001) 
in the R3R group and 14.0% (95% CI 2.3%, 24.3%; P=0.02) in the R3C group. By the PWP gap 
time model, efficacy against multiple episodes was 22.8% (95% CI 11.8%, 32.5%; P=0.0001) in 
the R3R group and 16.2% (95% CI 4.9%, 26.1%; P=0.006) in the R3C group. A summary of the 
four models is included in Table 3. Vaccine efficacy did not change during the rainy season, as 
indicated by the non-significant interaction between vaccine group and precipitation (hazard 
ratio of 0.99 (0.96, 1.03) in the R3C group and 1.00 (0.97, 1.04) in the R3R group) by the PWP 
total time model). 
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Table 3. Comparison of four models for estimating vaccine efficacy against all clinical 
malaria episodes 
 
Model R3R v. C3C 
(95% CI) 
p-value R3C v. C3C 
(95% CI) 
p-value 
Negative 
Binomial 
39.5% 
(26.1%, 50.5%) 
<0.001 20.9% 
(4.0%, 34.9%) 
0.017 
Andersen-Gill 39.2% 
(22.7%, 52.3%) 
<0.001 32.0% 
(13.7%, 46.4) 
0.002 
PWP Total Time 19.9% 
(8.3%, 30.0%) 
0.001 14.0% 
(2.3%, 24.3%) 
0.021 
PWP Gap Time 22.8% 
(11.8%, 32.5%) 
<0.001 16.2% 
(4.9%, 26.1%) 
0.006 
 
 
 
Clinical malaria episodes averted 
 
In our cohort, infants in the C3C group averaged 0.74 clinical malaria episodes per year, 0.63 
episodes among the R3C group, and 0.51 episodes among the R3R group. The estimated 
numbers of malaria cases per 100 infants that were averted were 10.9 cases per year in the R3C 
group and 22.7 cases per year in the R3R group, compared to the C3C group. Children in the 
C3C group averaged 0.48 episodes per year, 0.35 episodes among the R3C group, and 0.25 
episodes among the R3R group. The numbers of cases averted was 13.2 per 100 children per 
year in the R3C group and 23.5 per 100 children per year in the R3C group, compared to the 
C3C group. 
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Discussion 
 
It has been questioned if the performance of a malaria vaccine might vary depending on the 
seasonal pattern and intensity of transmission13, but this study is the first to suggest that efficacy 
does not change significantly across seasonal variation in precipitation and will provide valuable 
information for overall roll-out strategies for RTS,S/AS01. In Malawi, we showed that despite 
seasonal malaria transmission, the efficacy of the RTS,S/AS01 vaccine was not affected by 
seasonal variation in precipitation. Given that pilot programs will soon be underway to assess 
whether routine immunization can deliver the four-dose schedule effectively, whether the 
vaccine can prevent deaths, and whether the safety concerns indicated in phase 3 trials are 
significant, it would be a major blow to dispense with RTS,S/AS01. However, for these pilot 
programs to be successful, they must be implemented in a way that recognizes differences in 
vaccine performance across a variety of transmission intensity regions. Our study demonstrates 
that among seasonal transmission regions, implementation of the vaccine should not be given 
differential weighting based on precipitation patterns, nor should it be constrained to only certain 
times of year. 
 
In the Cox proportional hazards regression of efficacy against first episode of clinical malaria, 
precipitation was significantly associated with increased malaria incidence after a time lag of 1-3 
months, with a hazard ratio of 1.16 (95% CI 1.13, 1.19) among infants and 1.13 (95% CI 1.10, 
1.16) among children given a time lag of 2 months. This finding suggests that there is a strong, 
direct association between increased rainfall and increased malaria incidence given a time lag. 
Across both age groups, each additional inch of rainfall per month significantly increased the 
hazard of malaria by 13.0% (95% CI 9.9%, 16.2%; P<0.001). Precipitation in the rainy season 
(November through April) averaged 5.4 inches per month from 2009 through 2014 with a peak 
mean of 8.2 inches per month in January. Over each study year, malaria incidence was lowest 
during the period August through October of the dry season (Fig. 4). A previous study of malaria 
attack rates in Northern Ghana showed that the risk of infection was lowest during the period of 
2-3 months at the end of the dry season.14 The model showed that the level of rainfall most 
strongly predicted malaria incidence after a time lag of 2 months (60.5 days). This time lag is in 
line with previous time series analyses in a holoendemic area of Ghana and across the East 
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African highlands, which showed that high-resolution precipitation data could directly predict 
malaria incidence among children less than 15 years of age.15,16 This period of time also closely 
matches the theoretical vector-parasite-host cycle, which includes the growth of the Anopheles 
mosquito from egg to reproductive age, the development of the Plasmodium falciparum parasite 
in the vector from gametocytes to sporozoites, and the incubation period in the human host from 
infection to onset of malaria symptoms.17  
 
Figure 4. Seasonal precipitation and malaria incidence spike among infants and children in 
Lilongwe, Malawi, n=1513 
 
 
 
 
Age played an important factor in the number of clinical malaria episodes observed, with infants 
significantly more likely to experience multiple cases of malaria. In our cohort, infants in the 
control group averaged 0.79 clinical malaria episodes per year, whereas children in the control 
group averaged only 0.45 episodes per year. The hazard ratio between children and infants was 
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0.57 (95% CI 0.48, 0.67, p<0.0001) by the negative binomial model. This observed difference 
may in part be explained by differences in naturally acquired immunity and physiological effects 
between the two age groups,18 which led to RTS,S/AS01-induced anti-circumsporozoite antibody 
titres being significantly greater in children compared to infants.19 Interestingly, despite much 
higher vaccine efficacy among children (48.8% [95% CI 31.9%, 61.5%]) compared to infants 
(30.8% [95% CI 8.6%, 47.6%]) in the negative binomial model, we observed only a slightly 
greater number of total cases averted among children compared to infants. Compared to the C3C 
group, 22.7 and 10.9 infant clinical malaria cases per 100 infants per year were averted in the 
R3R and R3C groups, respectively, and 23.5 and 13.2 child clinical malaria cases per 100 
children per year were averted in the R3R and R3C groups, respectively. This similarity may 
have been due to somewhat longer follow-up times for children (median 45.3 months) compared 
to infants (median 34.1 months). 
 
Despite point estimate differences observed in the models for estimating vaccine efficacy against 
all clinical episodes, each of the four models showed significant efficacy in both the R3R and 
R3C groups compared to the C3C. In each instance, the PWP models (total time and gap time) 
indicated lower vaccine efficacies compared to the negative binomial and Andersen-Gill models 
(Table 3). The PWP total time model evaluates the effect of a covariate for the kth episode since 
study initiation and the PWP gap time model evaluates the effect of a covariate for the kth 
episode since time from the (k-1)th event. The PWP models may be more appropriate when the 
effects of covariates (e.g. vaccine, precipitation) are different in subsequent episodes, which is 
likely the case in the study of infectious diseases.12 However, the PWP models also have 
limitations. Notably, the risk set for later episodes becomes very small, making vaccine efficacy 
estimates potentially unstable when individuals get malaria numerous times.12 Further research 
must be conducted to determine the limitations and advantages of each model.  
 
Phase 4 clinical trials of RTS,S/AS01 will soon begin, with Malawi likely chosen as one of the 
study sites as early as 2017. Our phase 3 study is the first to suggest that vaccine efficacy does 
not change significantly across seasonal variation in precipitation and will provide valuable 
information for the roll-out of the vaccine in Malawi and other seasonal transmission sites. Based 
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on these findings, implementation of RTS,S/AS01 should not be given differential weighting 
based on seasonal rainfall, nor should delivery be constrained to only certain times of year. 
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